|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chow WH, Devesa SS, Warren JL and Fraumeni
JF Jr: Rising incidence of renal cell cancer in the United States.
JAMA. 281:1628–1631. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fry DE, Amin M and Harbrecht PJ: Rectal
obstruction secondary to carcinoma of the prostate. Ann Surgery.
189:488–492. 1979.
Motzer RJ, Bander NH and Nanus DM: Renal
cell carcinoma. N Engl J Med. 335:865–875. 1996.
|
|
4
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hudes G, Carducci M, Tomczak P, Dutcher J,
Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi
I, et al: Temsirolimus, interferon alfa, or both for advanced
renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rini BI, Escudier B, Tomczak P, Kaprin A,
Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME,
Rusakov IG, et al: Comparative effectiveness of axitinib versus
sorafenib in advanced renal cell carcinoma (AXIS): A randomised
phase 3 trial. Lancet. 378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic signoficance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. 7th. Wiley-Blackwell;
New Jersey: pp. 255–257. 2009
|
|
11
|
Pantuck AJ, Zisman A and Belldegrun AS:
The changing natural history of renal cell carcinoma. J Urol.
166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 22:3584–3590. 2009. View Article : Google Scholar
|
|
13
|
Faivre S, Delbaldo C, Vera K, Robert C,
Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et
al: Safety, pharmacokinetic, and antitumor activity of SU11248, a
novel oral multitarget tyrosine kinase inhibitor, in patients with
cancer. J Clin Oncol. 1:25–35. 2006. View Article : Google Scholar
|
|
14
|
Gore ME, Szczylik C, Porta C, Bracarda S,
Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano
D, et al: Safety and efficacy of sunitinib for metastatic
renal-cell carcinoma: An expanded-access trial. Lancet Oncol.
8:757–763. 2009. View Article : Google Scholar
|
|
15
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 6:1061–1068. 2010. View Article : Google Scholar
|
|
16
|
May M, Cindolo L, Zigeuner R, De Cobelli
O, Rocco B, De Nunzio C, Tubaro A, Coman I, Truss M, Dalpiaz O, et
al: Results of a comparative study analyzing octogenarians with
renal cell carcinoma in a competing risk analysis with patients in
the seventh decade of life. Urol Oncol. 32:1252–1258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Escudier B, Szczylik C, Hutson TE, Demkow
T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ,
Cella D, et al: Randomized phase II trial of first-line treatment
with sorafenib versus interferon Alfa-2a in patients with
metastatic renal cell carcinoma. J Clin Oncol. 8:1280–1289. 2009.
View Article : Google Scholar
|
|
18
|
Zhang HL, Qin XJ, Wang HK, Gu WJ, Ma CG,
Shi GH, Zhou LP and Ye DW: Clinicopathological and prognostic
factors for long-term survival in Chinese patients with metastatic
renal cell carcinoma treated with sorafenib: A single-center
retrospective study. Oncotarget. 6:36870–36883. 2015.PubMed/NCBI
|
|
19
|
Motzer RJ, Escudier B, Tomczak P, Hutson
TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J,
Hariharan S, et al: Axitinib versus sorafenib as second-line
treatment for advanced renal cell carcinoma: Overall survival
analysis and updated results from a randomised phase 3 trial.
Lancet Oncol. 14:552–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akaza H, Naito S, Ueno N, Aoki K, Houzawa
H, Pitman Lowenthal S and Lee SY: Real-world use of sunitinib in
Japanese patients with advanced renal cell carcinoma: Efficacy,
safety and biomarker analyses in 1689 consecutive patients. Jpn J
Clin Oncol. 45:576–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mickisch GH, Garin A, van Poppel H, de
Prijck L and Sylvester R; European organisation for research and
treatment of cancer (EORTC) genitourinary Group, : Radical
nephrectomy plus interferon-alfa-based immunotherapy compared with
interferon alfa alone in metastatic renal-cell carcinoma: A
randomised trial. Lancet. 358:966–970. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Flanigan RC, Salmon SE, Blumenstein BA,
Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N and Crawford
ED: Nephrectomy followed by interferon alfa-2b compared with
interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J
Med. 345:1655–1659. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Flanigan RC, Mickisch G, Sylvester R,
Tangen C, Van Poppel H and Crawford ED: Cytoreductive nephrectomy
in patients with metastatic renal cancer: A combined analysis. J
Urol. 171:1071–1076. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choueiri TK, Xie W, Kollmannsberger C,
North S, Knox JJ, Lampard JG, McDermott DF, Rini BI and Heng DY:
The impact of cytoreductive nephrectomy on survival of patients
with metastatic renal cell carcinoma receiving vascular endothelial
growth factor targeted therapy. J Urol. 185:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wood CG and Margulis V: Neoadjuvant
(presurgical) therapy for renal cell carcinoma: A new treatment
paradigm for locally advanced and metastatic disease. Cancer. 115
10 Suppl:S2355–S2360. 2009. View Article : Google Scholar
|
|
27
|
Powles T, Blank C, Chowdhury S, Horenblas
S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, et
al: The outcome of patients treated with sunitinib prior to planned
nephrectomy in metastatic clear cell renal cancer. Eur Urol.
60:448–454. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bex A, Blank C, Meinhardt W, van Tinteren
H, Horenblas S and Haanen J: A phase II study of presurgical
sunitinib in patients with metastatic clear-cell renal carcinoma
and the primary tumor in situ. Urology. 78:832–837. 2011.
View Article : Google Scholar : PubMed/NCBI
|
